Tech and Retail Giants See Mild Dips Amid Ratings, Upgrades, and New Releases

Generated by AI AgentAinvest Market Brief
Wednesday, Jul 31, 2024 6:00 pm ET1min read
C--
PLTR--
1. Palantir Technologies (NYSE: PLTR)
Palantir Technologies dipped mildly by -2.55%. Citigroup and Jefferies both maintain their ratings on Palantir Technologies, with Citigroup maintaining a "Neutral" rating and Jefferies holding a "Hold" rating. Both firms have raised the target price to $28.00. Palantir's Q1 2024 revenue was $6.34 billion.

2. Block (NYSE: SQ)
Block dipped mildly by -2.58%. Block will report its second-quarter financial results on August 1, 2024. Morgan Stanley maintains an underweight rating with a $55 target. Macquarie maintains an outperform rating with a $100 target. William Blair upgraded Block to outperform. An insider sold 2,500 shares on July 15, 2024.

3. Vertiv Holdings (NYSE: VRT)
Vertiv Holdings dipped mildly by -2.59%. Vertiv Holdings reported revenue of $35.92 billion and net profit of $1.72 billion in the first half of fiscal 2024, with a 28.99% year-over-year growth in net profit. Goldman Sachs maintained a buy rating with a revised target price of $104.00.

4. Nike (NYSE: NKE)
Nike dipped mildly by -2.62%. Nike reported fiscal 2024 revenue of $51.362 billion and net profit of $5.7 billion. Nike maintains a "hold" rating from TD Cowen, with a revised target price of $71. Nike remains a leading brand in the Olympic games.

5. Sony Group (NYSE: SONY)
Sony Group dipped mildly by -2.71%. Sony announced a DualSense wireless controller themed "Astro Bot" for $79.99, available for pre-order on August 9; PC version of "Bloodborne" successfully tested by players; PS VR2 sales surged after a $200 price drop; CineAlt cameras supported filmmakers at the FIRST festival.

Market Watch column provides a thorough analysis of stock market fluctuations and expert ratings.

Latest Articles

Stay ahead of the market.

Get curated U.S. market news, insights and key dates delivered to your inbox.

Comments



Add a public comment...
No comments

No comments yet